[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Farmoquimica S.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100653079","efficacy-of-a-dietary-supplement-for-telogen-effluvium-associated-with-glp-1-receptor-agonist-use-a-clinical-subjective-and-trichogram-evaluation-100653079",false,"NCT07783113","Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use","Estudo da eficácia de um Suplemento Alimentar na redução da Queda Capilar em Participantes Com eflúvio telógeno Associado ao Uso de análogos de GLP-1 Por Meio de avaliação clínica, percepção Subjetiva e Tricograma","GLP-1","Inclusion Criteria:\n\n* Female participants aged 20 to 60 years.\n* Dry, normal, combination, or oily scalp type.\n* Clinical diagnosis of telogen effluvium associated with the use of GLP-1 receptor agonists (semaglutide or tirzepatide), diagnosed by a dermatologist and confirmed by trichogram analysis.\n* Hair length of at least 3 cm.\n* Use of GLP-1 receptor agonists (semaglutide or tirzepatide) for at least 3 months prior to enrollment.\n* Intact skin in the study area (scalp).\n* Use of GLP-1 receptor agonists approved by ANVISA and commercially available in Brazil.\n* Under regular medical supervision during the study period.\n* Loss of at least 5% of initial body weight prior to enrollment.\n* Willingness to maintain the same hairstyle, haircut, and hair care habits throughout the study.\n* Willingness to comply with all study procedures and requirements.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, postpartum period up to 6 months, or intention to become pregnant during the study.\n* Scalp conditions or skin marks that may interfere with study assessments.\n* Known allergy or hypersensitivity to any component of the investigational product or similar products.\n* Active scalp disorders that could interfere with study evaluations, including scarring alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate-to-severe seborrheic dermatitis, or eczema.\n* Use of nonsteroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizing agents, or immunosuppressants within 2 weeks before enrollment.\n* Ongoing radiotherapy or chemotherapy treatment.\n* Hair chemical procedures within 30 days prior to enrollment.\n* Recent use or dose adjustment of medications known to induce telogen effluvium.\n* Use of dietary supplements for hair loss within the previous 3 months.\n* Use of hair loss treatments or hair cycle modulators (e.g., minoxidil, finasteride, dutasteride, spironolactone) within the previous 3 months.\n* Hair transplantation within the previous 18 months.\n* Use of topical dermatological products for therapeutic or specific cosmetic purposes on the study area (scalp), such as hair tonics, topical minoxidil, medicated lotions, or acid-based treatments, within 48 hours prior to study initiation.\n* Initiation, discontinuation, or modification of hormone therapy within the previous 3 months.\n* Uncontrolled systemic diseases, including diabetes, lupus, thyroid disorders, anemia, or documented iron deficiency.\n* Bariatric surgery within the previous 12 months.\n* Hair loss associated with COVID-19 infection within the previous 6 months.\n* Hospitalization within the previous 6 months.\n* Major physical or psychological stressors within the previous 3 months.\n* Uncontrolled endocrine disorders.\n* History or evidence of alcohol or substance abuse.\n* Immunosuppression caused by medications or active diseases.\n* Excessive sun exposure or artificial tanning within 15 days before the baseline visit.\n* Participation in another clinical study.\n* Investigator site staff or family members directly involved in the study.\n* Any condition that, in the investigator's opinion, may compromise participant safety or study integrity.",true,"FEMALE","20 Years","60 Years",{"count":22,"type":23},48,"ESTIMATED","INTERVENTIONAL",[26],"NA","A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days. Researchers will evaluate hair loss, hair density, and hair growth through clinical assessments, hair measurements (trichogram), and participant questionnaires.",[29],"Alopecia",[29,31,32,33],"Glucagon-Like Peptide-1 Receptor Agonists","Hair loss","Dietary Supplement","NOT_YET_RECRUITING","2026-08-25",{"date":37,"type":38},"2026-08-27","ACTUAL",{"date":40,"type":23},"2026-10",{"date":42,"type":23},"2027-02",{"name":44,"class":45},"Farmoquimica S.A.","INDUSTRY",""]